RxDoctor Payments Data

W William Cox, MD

Hematology & Oncology · Suite 1, AKNPI 1114912094

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,100 of the $3,397 with a category attached, or 61.8%. Pfizer accounts for 62.6% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $2,197, more than ten times the $138 reported in 2019.

$3,397in general payments, 2019–2025

Across 36 payments — averaging $94.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • Inari Medical, Inc.$796
  • Genentech USA, Inc.$114
  • AstraZeneca$99
  • E.r. Squibb & Sons, L.L.C.$48
  • Celltrion USA Inc.$34
  • plus $180 from 8 others

What the payments were for

  • Consulting fees$2,10062%
  • Food & beverage$1,28338%
  • Education$140%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology & oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,331,867
Medicare patients
363
Services billed
77,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide23$513,709
RevlimidLenalidomide25$429,669
Lenalidomide31$389,340
CalquenceAcalabrutinib Maleate19$320,149
ErleadaApalutamide20$301,830
VenclextaVenetoclax19$282,208
NubeqaDarolutamide15$195,370
Abiraterone Acetate77$157,951
XtandiEnzalutamide11$154,592
Imatinib Mesylate11$2,589
Hydroxyurea29$1,332
Dexamethasone26$1,100
Prochlorperazine Maleate48$910
Pantoprazole Sodium50$749
Acyclovir41$627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$48$513,70923 claims
AstraZenecaCalquence$99$320,14919 claims
Johnson & JohnsonErleada$28$301,83020 claims
AbbVieVenclexta$26$282,20819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Other hematology & oncology in Suite 1

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →